Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used for a novel Adeno-Associated Virus (AAV) gene therapy, GA-002, aimed at curing GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM).
Lead Product(s): GA-002
Therapeutic Area: Rare Diseases and Disorders Product Name: GA-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Genosera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 14, 2023
Details:
The net proceeds will be used to support a consortium of academic and private sector researchers tasked with the development of various AAV-based gene therapies to help develop a cure for Hereditary Inclusion Body Myopathy (HIBM).
Lead Product(s): GA-002
Therapeutic Area: Genetic Disease Product Name: GA-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Financing July 31, 2023